Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2010

View Archived Issues

Small molecules activating apoptotic procaspases identified

Novotyr Therapeutics presents IGF-1R inhibitors as antineoplastic agents

Studies demonstrate prediction of recurrence with Oncotype DX in colon cancer

Ark puts development of Vitor on hold following results from phase III study in NSCLC

Teva and AWD.pharma claim KCNQ channel activators for the treatment of pain

Achillion selects ACH-2684 as lead clinical candidate in hepatitis C infection program

Pfizer presents update on pipeline following acquisition of Wyeth in October 2009

GTC provides update for recombinant human Factor VIIa

Oncolytic choline kinase inhibitor TCD-717 to enter clinical development

Roche identifies selective P2X3 antagonist: RO-85

Arena discloses S1P1 receptor agonists for autoimmune/inflammatory conditions

DMI Life Sciences describes novel PKB/Akt and MMP-9 inhibitors

Novel beta-agonists for asthma therapy claimed by Gilead

SK Chemicals presents ALK4 and 5 inhibitors for the treatment of fibrosis

IDSMB recommends continuation of Basilea's phase III trial of isavuconazole

Genfit reports results from completed phase II trial of GFT-505

GTAC completes review of ReNeuron's supplemental preclinical data package for ReN-001

Amarin presents update on MARINE and ANCHOR phase III clinical trials of AMR-101

Spectrum receives payments from Nippon and Handok under agreements for EOquin

Diamyd to file for market approval of Diamyd diabetes vaccine in 2011

Watson acquires Eden Biodesign for approximately USD 15 million

Daiichi Sankyo submits NDA in Japan for long-acting CS-8958

European Commission approves Merck's MAA for fertility treatment Elonva

Phosphagenics reports results from phase Ib study of its transdermal oxycodone patch

FDA says Theravance's response to complete response letter for telavancin incomplete

Final phase II data support safety of picoplatin as alternative to oxaliplatin in metastatic CRC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...